# US 2002/0055462 A1 · Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0055462 A1
- Document ID: US20020055462A1
- Status: Published application
- Kind: A1
- Application number: 10/013,798
- Filed: 2001-12-10
- Published: 2002-05-09
- Earliest claimed: 1999-06-10
- Inventors: Michael John Reed; Barry Victor Lloyd Potter
- Web page: https://patentgrep.com/patent/US20020055462A1

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/566: having an oxo group in position 17, e.g. estrone
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided use of a material selected from (i) microtubule stabilizing agent; (ii) microtubule disrupter; (iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group; and (iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group, for the manufacture of a medicament for the inhibition of tumor necrosis factor α (TNFα) stimulated aromatase activity.

## Claims

### Claim 1

A composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
(i) microtubule stabilising agent;
(ii) microtubule disrupter;
(iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group; and
(iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) or at least one of (iv).

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) and at least one of (iv).

### Claim 4 (depends on 1)

The composition of claim 1, wherein (iii) is a compound of the formula C-D-E wherein C is an sulphamate group, D is a cyclic group, and E is an oxyhydrocarbyl group

### Claim 5 (depends on 1)

The composition of claim 1, wherein the cyclic group has a polycyclic ring structure.

### Claim 6 (depends on 4)

The composition of claim 4, wherein Group A and/or Group C and/or Group E is linked or attached to the ring.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the polycyclic ring structure comprises three six-membered rings.

### Claim 8 (depends on 5)

The composition of claim 5, wherein Group A and/or Group C and/or Group E are attached to the same ring of the polycyclic ring structure.

### Claim 9 (depends on 5)

The composition of claim 5, wherein the polycyclic ring structure is a steroidal ring structure

### Claim 10 (depends on 4)

The composition of claim 4, wherein Group A or Group C and/or Group E are attached to the same ring of the cyclic compound of the present invention at positions ortho with respect to each other.

### Claim 11 (depends on 9)

The composition of claim 9, wherein Group A or Group E is attached to the 2 position of the A ring of the steroidal structure.

### Claim 12 (depends on 9)

The composition of claim 9, wherein Group C is attached to the 3 position of the A ring of the steroidal structure.

### Claim 13 (depends on 1)

The composition of claim 1, wherein Group A is of the formula C1-6O (such as a C1-3O).

### Claim 14 (depends on 1)

The composition of claim 1, wherein Group A is an alkoxy.

### Claim 15 (depends on 9)

The composition of claim 9, wherein Group A is a methoxy substituent at the 2 position of the steroidal ring structure.

### Claim 16 (depends on 1)

The composition of claim 1, wherein Group C is a group of the formula
11
wherein each of R1 and R2 is independently selected from H or a hydrocarbyl group.

### Claim 17 (depends on 16)

The composition of claim 16, wherein R1 and R2 are independently selected from H or alkyl, cycloalkyl, alkenyl and aryl, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

### Claim 18 (depends on 16)

The composition of claim 16, wherein at least one of R1 and R2 is H.

### Claim 19 (depends on 1)

The composition of claim 1, wherein (iv) is a C1-6 (such as a C1-3) alkoxy derivative of oestrone-3-O-sulphamate, preferably a 2-C1-6 alkoxy derivative of oestrone-3-O-sulphamate.

### Claim 20 (depends on 1)

The composition of claim 1, wherein (iv) is 2-methoxyoestrone-3-O-sulphamate.

### Claim 21 (depends on 1)

The composition of claim 1, wherein (ii) is selected from the group consisting of human EMAP-like protein-70, paclitaxel (Taxol), colchicine, vinca alkaloids, vinblastine, and nocodazole or derivatives thereof.

### Claim 22 (depends on 1)

The composition of claim 1, wherein (ii) is paclitaxel.

### Claim 23 (depends on 1)

The composition of claim 1, wherein (iii) is 2-methoxyoestradiol.

### Claim 24 (depends on 1)

The composition of claim 1, wherein (i) is selected from the group consisting of doublecortin, paclitaxel (Taxol), tubercidin, docetaxel (Taxotere), epothilones, (−)-laulimalide, and discodermolide or derivatives thereof.

### Claim 25

A method of making a composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromastase activity, wherein the composition comprises at least one of:
(i) microtubule stabilising agent;
(ii) microtubule disrupter;
(iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group; and
(iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) or at least one of (iv).

### Claim 27 (depends on 25)

The composition of claim 25, wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) and at least one of (iv).

### Claim 28

A pharmaceutical composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
(i) microtubule stabilising agent;
(ii) microtubule disrupter;
(iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group; and
(iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) or at least one of (iv).

### Claim 30 (depends on 28)

The pharmaceutical composition of claim 28, wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) and at least one of (iv).

### Claim 31

A method of making a pharmaceutical composition for the inhibition of tumour necrosis factor a (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
(i) microtubule stabilising agent;
(ii) microtubule disrupter;
(iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group; and
(iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.

### Claim 32 (depends on 31)

The method of claim 31, wherein wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) or at least one of (iv).

### Claim 33 (depends on 31)

The method of claim 31, wherein wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) and at least one of (iv).

### Claim 34

A method of treating a patient in need thereof, with the pharmaceutical composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
(i) microtubule stabilising agent;
(ii) microtubule disrupter;
(iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group; and
(iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.

### Claim 35 (depends on 34)

The method of claim 34, wherein wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) or at least one of (iv).

### Claim 36 (depends on 34)

The method of claim 34, wherein wherein the composition comprises at least one of (i) or at least one of (ii) and at least one of (iii) and at least one of (iv).
